Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CHF

- PMLiVE

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

Findings demonstrated a 71% reduction in cancer spreading and death

- PMLiVE

Astellas strengthens US and Canadian leadership team

Steve Sabus, Lynn Gerber and Kevin O’Keefe are promoted to new roles

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

- PMLiVE

Astellas promotes Anthony Fiordaliso to VP, Americas finance

He first joined the pharma firm in 2010 from Schering-Plough

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

- PMLiVE

FDA fast-tracks Astellas’ Rydapt rival

AML treatment gilteritinib is currently involved in four phase III trials

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links